Welcome to our dedicated page for Rubius Therapeutics news (Ticker: RUBY), a resource for investors and traders seeking the latest updates and insights on Rubius Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rubius Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rubius Therapeutics's position in the market.
Rubius Therapeutics (Nasdaq:RUBY) announced that it will present clinical results from its Phase 1/2 study of RTX-240 in advanced solid tumors at the AACR Virtual Annual Meeting from April 10-15, 2021. The study aims to enhance immune response while minimizing toxicity. Key findings from the initial five cohorts (n=14) revealed no severe treatment-related adverse events and significant activation of NK and T cells. RTX-240 is designed to stimulate the immune system, potentially broadening therapeutic options for patients with solid tumors and hematologic malignancies.
Rubius Therapeutics (Nasdaq:RUBY) reported strong execution in 2020, advancing clinical trials for RTX-240 and RTX-321 while enhancing manufacturing capabilities. Key takeaways from initial RTX-240 trials indicate activation of both NK and T cells without severe adverse events. As of early 2021, the company continues patient enrollment for RTX-240 in relapsed/refractory acute myeloid leukemia and is screening patients for RTX-321 targeting HPV 16-positive cancers. Anticipated catalysts include additional clinical data releases and commencing patient dosing for RTX-321.
Rubius Therapeutics (Nasdaq: RUBY) announced that CEO Pablo J. Cagnoni and the executive team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 11:20 a.m. EST. A live audio webcast will be available on the company’s website, with a replay accessible for 90 days post-event.
Rubius Therapeutics is focused on developing Red Cell Therapeutics™, a proprietary platform aimed at treating cancer and autoimmune diseases. The company has been recognized as a top workplace in Massachusetts and Rhode Island.
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company, plans to announce its fourth quarter and full year 2020 financial results on February 23, 2021, prior to market open. The company is focused on developing Red Cell Therapeutics™ aimed at treating cancer and autoimmune diseases using its proprietary RED PLATFORM®. Notably, Rubius' manufacturing site was recognized as one of the 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies.
Rubius Therapeutics, a clinical-stage biopharmaceutical company, announced on February 3, 2021, that its CEO, Pablo J. Cagnoni, M.D., and the executive management team will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days. This event is scheduled for February 11, 2021, at 2:30 p.m. EST. A live audio webcast will be available on the company’s website, with an archived replay accessible for 90 days. Rubius is focused on developing Red Cell Therapeutics™ for cancer and autoimmune diseases, leveraging its proprietary RED PLATFORM®.
Rubius Therapeutics (RUBY) announced significant advancements in its oncology pipeline and manufacturing capabilities. Initial data from the Phase 1 trial of RTX-240 show effective activation of innate and adaptive immunity, with no severe adverse events reported. Patient screening for the RTX-321 trial has commenced, targeting advanced HPV-positive cancers. The company has improved productivity at its manufacturing facility, achieving a longer shelf life for products. Rubius aims to present more clinical results in early 2021 and expand its pipeline further.
Rubius Therapeutics (Nasdaq:RUBY) announces that CEO Pablo J. Cagnoni will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 8:20 a.m. ET. The presentation will showcase Rubius' innovative work in developing Red Cell Therapeutics™, a new class of medicines aimed at treating cancer and autoimmune diseases using the proprietary RED PLATFORM®. A live audio webcast will be available on the company’s website, with an archived replay accessible for 90 days.
Rubius Therapeutics (Nasdaq:RUBY) announced participation by CEO Pablo J. Cagnoni in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 11:45 a.m. EST. A live audio webcast will be accessible in the Investors & Media section of the company's website, with an archived replay available for 90 days post-event. Rubius Therapeutics focuses on developing Red Cell Therapeutics™, utilizing its proprietary RED PLATFORM® for treating diseases like cancer and autoimmune disorders.
Rubius Therapeutics (Nasdaq:RUBY) announced that its CEO, Pablo J. Cagnoni, M.D., will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020. The presentation is scheduled for 3:15 p.m. GMT/10:15 a.m. EST. A live audio webcast will be accessible on the company's website, with an archived replay available for 90 days post-event. Rubius specializes in genetically engineering red blood cells to create Red Cell Therapeutics™, aiming to treat cancer and autoimmune diseases through innovative cellular therapies.
Rubius Therapeutics (Nasdaq:RUBY) reported Q3 2020 results, showing a net loss of $40.9 million ($0.51/share), down from $47 million ($0.59/share) a year prior. The company completed dosing the fourth cohort in the RTX-240 Phase 1/2 clinical trial and dosed the first patient in the AML trial. Rubius filed an IND for RTX-321, which includes frozen drug substance, promising an off-the-shelf cellular therapy. R&D expenses were $28.2 million, lower than last year due to deprioritization of rare disease projects, while G&A expenses fell to $12 million from $15 million. Cash reserves stand at $207.9 million, supporting operations into 2022.
FAQ
What is the market cap of Rubius Therapeutics (RUBY)?
